A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis

Cysteine palmitoylation (S-palmitoylation) is a reversible post-translational modification that is installed by the DHHC family of palmitoyltransferases and is reversed by several acyl protein thioesterases 1 , 2 . Although thousands of human proteins are known to undergo S-palmitoylation, how this...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 586; no. 7829; pp. 434 - 439
Main Authors Zhang, Mingming, Zhou, Lixing, Xu, Yuejie, Yang, Min, Xu, Yilai, Komaniecki, Garrison Paul, Kosciuk, Tatsiana, Chen, Xiao, Lu, Xuan, Zou, Xiaoping, Linder, Maurine E., Lin, Hening
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 15.10.2020
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cysteine palmitoylation (S-palmitoylation) is a reversible post-translational modification that is installed by the DHHC family of palmitoyltransferases and is reversed by several acyl protein thioesterases 1 , 2 . Although thousands of human proteins are known to undergo S-palmitoylation, how this modification is regulated to modulate specific biological functions is poorly understood. Here we report that the key T helper 17 (T H 17) cell differentiation stimulator, STAT3 3 , 4 , is subject to reversible S-palmitoylation on cysteine 108. DHHC7 palmitoylates STAT3 and promotes its membrane recruitment and phosphorylation. Acyl protein thioesterase 2 (APT2, also known as LYPLA2) depalmitoylates phosphorylated STAT3 (p-STAT3) and enables it to translocate to the nucleus. This palmitoylation–depalmitoylation cycle enhances STAT3 activation and promotes T H 17 cell differentiation; perturbation of either palmitoylation or depalmitoylation negatively affects T H 17 cell differentiation. Overactivation of T H 17 cells is associated with several inflammatory diseases, including inflammatory bowel disease (IBD). In a mouse model, pharmacological inhibition of APT2 or knockout of Zdhhc7 —which encodes DHHC7—relieves the symptoms of IBD. Our study reveals not only a potential therapeutic strategy for the treatment of IBD but also a model through which S-palmitoylation regulates cell signalling, which might be broadly applicable for understanding the signalling functions of numerous S-palmitoylation events. The dynamic and reversible S-palmitoylation of the transcription factor STAT3 enhances its activation and promotes the differentiation of T H 17 cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Author contributions M.Z. and H.L. designed the study; M.Z. carried out the cell experiments and the protein analysis; M.Z. and X.C. performed the click chemistry analysis; L.Z. [Author: Please clarify which author this refers to, as there seems to be no one with these initials in the author list. Should this be L.Z.?] and Yuejie Xu collected the human samples and performed the analyses; M.Y. carried out the chemical synthesis; Yilai Xu [Author: Is this Yilai Xu?], G.P.K. and T.K. repeated key cellular biochemical experiments with both DHHC7 and APT2; X.L. and M.Z. carried out the mouse experiments; M.Z. [Author: Please clarify which author this refers to; should this be M.Z.?] and H.L. drafted the manuscript with inputs from all authors; X.Z. directed the patient study; M.E.L. provided all of the DHHC plasmids and participated in data analysis; and H.L. directed the biochemical studies. All authors read and approved the final manuscript.
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/s41586-020-2799-2